Leonard Bell - Alexion Pharmaceuticals

Leonard Bell
CEO, Alexion

Total Compensation: $13.599 million

Professional Profile: Dr. Bell, 54, is actually one of the scientists who developed Soliris, the rare-disease drug that is Alexion's ($ALXN) bread and butter and the most expensive treatment in the world. Before co-founding Alexion in 1992, Bell was an assistant professor of medicine and pathology at Yale University School of Medicine, where he also attended medical school. He's still on the faculty there as an adjunct assistant professor. Bell took Alexion through an IPO in 1996.

Compensation Breakdown: $1.1 million in salary, $2.84 million in stock, and $6.84 million worth of options, plus $2.8 million in incentive pay and $15,021 in other compensation.

Company Performance: Alexion started 2012 with a new asset in its pocket. As 2011 came to a close, the company had wrapped up a deal for the Canadian biotech, Enobia, and its in-development treatment for hypophosphatasia, with $610 million up front and the promise of $470 million in milestone payments. The buyout was an important step toward diversifying Alexion's lineup beyond the very successful rare-disease drug Soliris, which is now approved in 40 countries. By June, the company had made plans for a new headquarters in New Haven, CT, to house its fast-growing staff. Then, in October, new data showed Soliris' benefits in another rare disease--relapsing neuromyelitis optica--a step toward a new indication for that drug. Soliris ended the year with $1.13 billion in sales, a 45% increase.

For more:
Pricey Soliris performs in another rare disease
Now, every pharma wants a $440K drug like Alexion's
Booming Alexion blueprints new HQ, plans for 300 new hires
R&D success puts Alexion at the top of the M&A list
Alexion scoops up rare disease drug in $1.08B Enobia buyout

Leonard Bell - Alexion Pharmaceuticals

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.